IRISYS, LLC. founded in 1996, has grown from a small laboratory focused on formulation development to an organization that provides a full spectrum of pharmaceutical product development contract services designed to move compounds from early research to Phase I/II clinical trials. Recro® acquired IriSys in August 2021.
Recro® is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of small molecule therapeutic dosage forms. With expertise in solving complex manufacturing problems, Recro is a leading CDMO providing primarily small molecule therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, high potency compound development, packaging, and logistics services to the global pharmaceutical market. In addition to our experience handling DEA controlled substances and developing and manufacturing modified release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, totaling 145,000 square feet, in Gainesville, Georgia, and San Diego, California.